Increased Risk of Non-Fatal Myocardial Infarction Following Testosterone Therapy Prescription in Men
Top Cited Papers
Open Access
- 29 January 2014
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (1), e85805
- https://doi.org/10.1371/journal.pone.0085805
Abstract
An association between testosterone therapy (TT) and cardiovascular disease has been reported and TT use is increasing rapidly. We conducted a cohort study of the risk of acute non-fatal myocardial infarction (MI) following an initial TT prescription (N = 55,593) in a large health-care database. We compared the incidence rate of MI in the 90 days following the initial prescription (post-prescription interval) with the rate in the one year prior to the initial prescription (pre-prescription interval) (post/pre). We also compared post/pre rates in a cohort of men prescribed phosphodiesterase type 5 inhibitors (PDE5I; sildenafil or tadalafil, N = 167,279), and compared TT prescription post/pre rates with the PDE5I post/pre rates, adjusting for potential confounders using doubly robust estimation. In all subjects, the post/pre-prescription rate ratio (RR) for TT prescription was 1.36 (1.03, 1.81). In men aged 65 years and older, the RR was 2.19 (1.27, 3.77) for TT prescription and 1.15 (0.83, 1.59) for PDE5I, and the ratio of the rate ratios (RRR) for TT prescription relative to PDE5I was 1.90 (1.04, 3.49). The RR for TT prescription increased with age from 0.95 (0.54, 1.67) for men under age 55 years to 3.43 (1.54, 7.56) for those aged ≥75 years (ptrend = 0.03), while no trend was seen for PDE5I (ptrend = 0.18). In men under age 65 years, excess risk was confined to those with a prior history of heart disease, with RRs of 2.90 (1.49, 5.62) for TT prescription and 1.40 (0.91, 2.14) for PDE5I, and a RRR of 2.07 (1.05, 4.11). In older men, and in younger men with pre-existing diagnosed heart disease, the risk of MI following initiation of TT prescription is substantially increased.Keywords
This publication has 30 references indexed in Scilit:
- Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trialsBMC Medicine, 2013
- Endogenous testosterone and cardiovascular disease in healthy men: a meta-analysisHeart, 2010
- Testosterone Deficiency and Replacement in Older MenThe New England Journal of Medicine, 2010
- Adverse Events Associated with Testosterone AdministrationThe New England Journal of Medicine, 2010
- Adverse Effects of Testosterone Therapy in Adult Men: A Systematic Review and Meta-AnalysisJournal of Clinical Endocrinology & Metabolism, 2010
- Mechanisms of thrombosis related to hormone therapyThrombosis Research, 2009
- Examination of Platelet Function in Whole Blood Under Dynamic Flow Conditions With the Cone and Plate(let) AnalyzerAmerican Journal of Clinical Pathology, 2007
- Cardiovascular safety of sildenafil citrate (Viagra®): An updated perspectiveUrology, 2006
- Doubly Robust Estimation in Missing Data and Causal Inference ModelsBiometrics, 2005
- Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal WomenJama-Journal Of The American Medical Association, 1998